We read with interest the article by Sanguinetti et al. titled “Fatal Pulmonary Infection Due to Multidrug-Resistant Mycobacterium abscessus in a Patient with Cystic Fibrosis,” which appeared in the February 2001 issue (5). We would like to point out some additional information relating to the authors' comment, “to our knowledge, this is the first evidence of true resistance to clarithromycin, which is considered the most active drug against M. chelonae.” First, the case report involves Mycobacterium abscessus, not M. chelonae. The two names are not synonymous and should not be used interchangeably (10). The organisms have different biologies, are readily differentiated in the laboratory, and have different drug susceptibilities (2, 3, 6, 8). (Essentially all cases of chronic lung disease caused by rapidly growing mycobacteria in the setting of cystic fibrosis are due to M. abscessus [3].)
Second, there have been several previous reports of acquired clarithromycin resistance in isolates of M. abscessus and the closely related M. chelonae, and the genetics of this resistance have been well characterized (7, 9, 11). We would especially call the authors' attention to an article describing the study of clarithromycin resistance in a series of 800 isolates of M. chelonae and M. abscessus. Eighteen of 800 clinical isolates (2.3%) submitted for susceptibility testing between 1990 and 1995 were found to be resistant to clarithromycin; 10 of these isolates were M. abscessus (9). The underlying conditions most commonly associated with the development of macrolide resistance in M. abscessus following clarithromycin therapy were cystic fibrosis (as in the case reported by the authors) and disseminated cutaneous disease. Sequencing studies of the 23S rRNA gene revealed that 94% of the clarithromycin-resistant isolates had a mutation involving the adenine at position 2058 or 2059 (Escherichia coli numbering system). Selected laboratory mutants resistant to clarithromycin had the same mutations, as have other species of mycobacteria and bacteria with acquired clarithromycin resistance (1, 4). The study also revealed that M. chelonae and M. abscessus have only a single copy of the ribosomal operon in their genome and hence demonstrate susceptibility to a single point mutation resulting in high-level (clinical) resistance.
REFERENCES
- 1.Alarcón T, Domingo D, Prieto N, López-Brea M. PCR using 3′-mismatched primers to detect A2142C mutation in 23S rRNA conferring resistance to clarithromycin in Helicobacter pyloriclinical isolates. J Clin Microbiol. 2000;38:923–925. doi: 10.1128/jcm.38.2.923-925.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Brown B A, Wallace R J, Jr, Onyi G, DeRosas V, Wallace R J., III Activities of four macrolides, including clarithromycin, against Mycobacterium fortuitum, Mycobacterium chelonae, and M. chelonae-like organisms. Antimicrob Agents Chemother. 1992;36:180–184. doi: 10.1128/aac.36.1.180. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Griffith D E, Girard W M, Wallace R J., Jr Clinical features of pulmonary disease caused by rapidly growing mycobacteria: “Analysis of 154 patients.”. Am Rev Respir Dis. 1993;147:1271–1278. doi: 10.1164/ajrccm/147.5.1271. [DOI] [PubMed] [Google Scholar]
- 4.Pina M, Occhialini A, Monteiro L, Doermann H-P, Mégraud F. Detection of point mutations associated with resistance of Helicobacter pylorito clarithromycin by hybridization in liquid phase. J Clin Microbiol. 1998;36:3285–3290. doi: 10.1128/jcm.36.11.3285-3290.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Sanguinetti M, Ardito F, Fiscarelli E, La Sorda M, D'Argenio P, Ricciotti G, Fadda G. Fatal pulmonary infection due to multidrug-resistant Mycobacterium abscessusin a patient with cystic fibrosis. J Clin Microbiol. 2001;39:816–819. doi: 10.1128/JCM.39.2.816-819.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Swenson J M, Wallace R J, Jr, Silcox V A, Thornsberry C. Antimicrobial susceptibility of five subgroups of Mycobacterium fortuitum and Mycobacterium chelonae. Antimicrob Agents Chemother. 1985;28:807–811. doi: 10.1128/aac.28.6.807. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Tebas P, Sultan F, Wallace R J, Jr, Fraser V. Rapid development of resistance to clarithromycin following monotherapy for disseminated Mycobacterium chelonaeinfection in a heart transplant patient. Clin Infect Dis. 1995;20:443–444. doi: 10.1093/clinids/20.2.443. [DOI] [PubMed] [Google Scholar]
- 8.Wallace R J, Jr, Brown B A, Onyi G. Skin, soft tissue, and bone infections due to Mycobacterium chelonae subspecies chelonae—importance of prior corticosteroid therapy, frequency of disseminated infections, and resistance to oral antimicrobials other than clarithromycin. J Infect Dis. 1992;166:405–412. doi: 10.1093/infdis/166.2.405. [DOI] [PubMed] [Google Scholar]
- 9.Wallace R J, Jr, Meier A, Brown B A, Zhang Y, Sander P, Onyi G O, Böttger E C. Genetic basis for clarithromycin resistance among isolates of Mycobacterium chelonae and Mycobacterium abscessus. Antimicrob Agents Chemother. 1996;40:1676–1681. doi: 10.1128/aac.40.7.1676. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Wallace R J, Jr, Silcox V, Brown B A. Taxonomy of rapidly growing mycobacteria. Clin Infect Dis. 1994;18:121–122. doi: 10.1093/clinids/18.1.121. [DOI] [PubMed] [Google Scholar]
- 11.Wallace R J, Tanner D, Brennan P J, Brown B A. Clinical trial of clarithromycin for cutaneous (disseminated) infection due to Mycobacterium chelonae. Ann Int Med. 1993;119:482–486. doi: 10.7326/0003-4819-119-6-199309150-00006. [DOI] [PubMed] [Google Scholar]